SoftBank-backed Vir Biotechnology raises $143 million in U.S. IPO
NEW YORK (Reuters) - Vir Biotechnology <VIR.O> priced its initial public offering (IPO) at $20 a share on Thursday, at the bottom end of expectations, a fresh blow for SoftBank Group Corp's <9984.T> Vision Fund, owner of 21% in the infectious disease researcher.
San Francisco-based Vir raised $142.9 million having previously set a price range of $20-$22 per share. The IPO valued Vir at $2.2 billion.
(Reporting by Joshua Franklin in New York; Editing by Tom Hogue)
© Copyright Reuters Ltd. All rights reserved. The information contained in this news report may not be published, broadcast or otherwise distributed without the prior written authority of Reuters Ltd.